Vir Biotechnology Inc
NASDAQ:VIR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.74
12.66
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VIR stock under the Base Case scenario is 1.74 USD. Compared to the current market price of 7.12 USD, Vir Biotechnology Inc is Overvalued by 75%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Vir Biotechnology Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VIR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Vir Biotechnology Inc
Balance Sheet Decomposition
Vir Biotechnology Inc
Current Assets | 1B |
Cash & Short-Term Investments | 914.5m |
Other Current Assets | 132.7m |
Non-Current Assets | 451.2m |
Long-Term Investments | 271.5m |
PP&E | 125.6m |
Intangibles | 36.2m |
Other Non-Current Assets | 17.9m |
Current Liabilities | 117.2m |
Accounts Payable | 7.3m |
Accrued Liabilities | 94.7m |
Other Current Liabilities | 15.2m |
Non-Current Liabilities | 140.5m |
Other Non-Current Liabilities | 140.5m |
Earnings Waterfall
Vir Biotechnology Inc
Revenue
|
78.6m
USD
|
Cost of Revenue
|
-959k
USD
|
Gross Profit
|
77.7m
USD
|
Operating Expenses
|
-647.8m
USD
|
Operating Income
|
-570.1m
USD
|
Other Expenses
|
36.7m
USD
|
Net Income
|
-533.3m
USD
|
Free Cash Flow Analysis
Vir Biotechnology Inc
USD | |
Free Cash Flow | USD |
VIR Profitability Score
Profitability Due Diligence
Vir Biotechnology Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Vir Biotechnology Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
VIR Solvency Score
Solvency Due Diligence
Vir Biotechnology Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Vir Biotechnology Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VIR Price Targets Summary
Vir Biotechnology Inc
According to Wall Street analysts, the average 1-year price target for VIR is 30.09 USD with a low forecast of 10.1 USD and a high forecast of 115.5 USD.
Dividends
Current shareholder yield for VIR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
VIR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 444 full-time employees. The company went IPO on 2019-10-11. The company has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The firm's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. The company is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.
Contact
IPO
Employees
Officers
The intrinsic value of one VIR stock under the Base Case scenario is 1.74 USD.
Compared to the current market price of 7.12 USD, Vir Biotechnology Inc is Overvalued by 75%.